美托洛尔联合曲美他嗪治疗冠心病心力衰竭的疗效及安全性分析

Effect and Safety Analysis of Metoprolol Combined With Trimetazidine in Treatment of Coronary Heart Disease and Heart Failure

目的分析治疗冠心病心力衰竭应用美托洛尔联合曲美他嗪的临床疗效及安全性。方法56例冠心病心力衰竭患者为我科2019年1月至2019年12月收治,根据患者治疗意愿将其分为对照组与观察组,各28例。将应用美托洛尔治疗的患者作为对照组,将应用美托洛尔联合曲美他嗪治疗的患者作为观察组,对两组治疗总有效率、不良反应发生率以及治疗前后的心功能指标进行比较。结果观察组治疗总有效率较对照组高(P<0.05)。观察组不良反应发生率较对照组低(P<0.05)。观察组治疗后LVESD、LVEDD较对照组低,观察组6MWT、LVEF较对照组高,均(P<0.05)。结论治疗冠心病心力衰竭应用美托洛尔联合曲美他嗪效果显著,安全性高。

Objective To analyze clinical effect and safety of metoprolol combined with trimetazidine in treatment of coronary heart disease and heart failure.Methods The paper chose 56 cases coronary heart disease and heart failure patients in our department from January 2019 to December 2019,and divided them into control group and observation group according to their treatment willingness,28 cases in each group.Control group was treated with metoprolol,and observation group with metoprolol combined with trimetazidine.Total effective rate,incidence of adverse reactions and cardiac function indexes before and after treatment were compared between two groups.Results Total effective rate of observation group was higher than control group(P<0.05).Incidence of adverse reactions in observation group was lower than control group(P<0.05).After treatment,LVESD and LVEDd in observation group were lower than control group,and 6MWT and LVEF in observation group were higher than control group(P<0.05).Conclusion Metoprolol combined with trimetazidine can achieve significant effect and high safety in treatment of coronary heart disease and heart failure.